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Several types of GFI1B variants have been identified in patients with inherited bleeding and platelet 
disorders. This includes dominant-negative truncating variants affecting DNA binding,1-4 missense 
variants of which the molecular mechanism is unclear,5-7 and variants changing the amount and ratio 
of GFI1B isoforms (Figure S1).7, 8 The severity of the bleeding disorder may differ depending on the 
type of variant, but frequent abnormalities include macrothrombocytopenia, a reduction in α-
granule numbers, and platelet CD34 expression. In this study we performed a molecular and/or 
clinicopathological characterization of eight GFI1B variants in non-DNA binding domains (Figure S1). 
These variants were previously identified by the NIHR BioResource rare disease study in cases with 
an assumed inherited bleeding or platelet disorder.9 Molecular characterization was not performed 
for D23N, since the minor allele frequency in the gnomAD database deemed too high for a causal 
variant. From the characterization of the other variants we can conclude that although some have a 
clear effect on GFI1B function, they are not necessarily sufficient to cause bleedings on their own. 
 Previously, we used the megakaryoblast cell line MEG-01 to study the effect of GFI1B and the 
proven pathogenic GFI1B-Q287* variant on cell expansion. In expansion-competition cultures 
containing transduced and non-transduced cells, MEG-01 cells ectopically expressing GFI1B were 
overgrown by non-transduced cells, while the opposite was observed following expression of GFI1B-
Q287* (Figure 1; manuscript resubmitted September 2018). Thus, forced GFI1B expression inhibits 
MEG-01 cell expansion whereas dominant-negative GFI1B-Q287* results in enhanced expansion. The 
latter is in line with elevated megakaryocyte numbers observed in a bone marrow specimen of a 
GFI1B p.Q287* affected individual.1 To investigate the (functional) effect of GFI1B variants, we 
retrovirally expressed them in MEG-01 cells and performed the expansion-competition culture 
described above. GFI1B and GFI1B-Q287* were taken along as references. Two variants, one in the 
intermediate domain (G139S) and one in zinc finger (znf) 2 (G198S), did not affect the inhibitory 
function of wild type GFI1B on MEG-01 proliferation (Figure 1A, Figure 1B). The R190W variant, 
located between znf1 and znf2, rendered the protein less effective at inhibiting MEG-01 proliferation 
(Figure 1C), whilst both the znf1 variant C168F and the truncated variant Q89fs rendered the protein 
completely inactive (Figure 1D, Figure 1E). Interestingly, expression of znf1 H181Y and R184P variants 
resulted in increased MEG-01 cell proliferation, although to a lesser extent than cells expressing 
GFI1B-Q287* (Figure 1F, Figure 1G). To further study H181Y and R184P, we introduced these variants 
separately in GFI1B-Q287*. This led to partial inhibition of the growth stimulating effect of GFI1B-
Q287* (Figure 2A, Figure 2B), indicating that amino acids H181 and R184 are important for the effect 
of GFI1B-Q287* on MEG-01 proliferation. These findings clearly demonstrate that different variants 
have qualitatively distinct effects on the function of GFI1B, and that znf1 is important in regulating 
MEG-01 proliferation.  
 The increased MEG-01 expansion caused by GFI1B-H181Y and GFI1B-R184P suggests that 
these variants, like GFI1B-Q287*, act in a dominant-negative manner. However, the molecular 
mechanism might be different, because these variants are not located in the DNA binding domain 
like GFI1B-Q287*. GFI1B is a repressive transcription factor that inhibits its own transcription and 
that of its paralogue GFI1.10, 11 GFI1B-Q287* has lost this repressive function.1 To study if the variants 
affect the repressive function of GFI1B, we performed gene reporter assays using the Gfi1 promoter. 
Remarkably, all tested GFI1B missense variants, including GFI1B-H181Y and GFI1B-R184P, repressed 
the Gfi1 promoter to a similar extent as wild type GFI1B (Figure 2C). However, results obtained in 
transient gene repression assays may not reflect effects on endogenous target genes. We therefore 
analyzed the effects of GFI1B-H181Y and GFI1B-R184P on endogenous GFI1B expression. Wild type 
GFI1B, GFI1B-Q287*, GFI1B-H181Y, and GFI1B-R184P were expressed in MEG-01 cells, followed by 
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endogenous GFI1B mRNA expression analysis. In line with earlier reports, wild type GFI1B inhibited 
endogenous GFI1B expression.12 In contrast, GFI1B-Q287*, as well as GFI1B-H181Y and GFI1B-R184P 
did not repress endogenous GFI1B expression to the same extent as wild type GFI1B (Figure 2D). This 
indicates that not only the DNA binding znfs, but also amino acids H181 and R184 are required for 
efficient repression of endogenous GFI1B. 
 The LSD1-RCOR1-HDAC co-repressor complex is one of the main epigenetic regulatory 
complexes recruited by GFI1B to induce transcriptional repression. To study whether GFI1B-H181Y- 
and GFI1B-R184P-induced MEG-01 expansion depends on an interaction with this complex, we co-
introduced a P2A mutation in the GFI1B-H181Y or GFI1B-R184P variants. The P2A mutation in the N-
terminal SNAG domain of GFI1B abrogates its interaction with LSD1,13 and nullifies the inhibitory 
effect of wild type GFI1B and stimulatory effect of GFI1B-Q287* on MEG-01 proliferation (manuscript 
resubmitted September 2018). Expression of the P2A-H181Y and P2A-R184P double mutants 
resulted in expansion rates similar to empty vector transduced cells (Figure 2E). This strongly 
suggests that H181Y and R184P variants require the LSD1 interaction to exert their effect on MEG-01 
expansion.  
 The functional data were subsequently correlated with clinical and laboratory features of 
patient samples to improve classification of the GFI1B variants according to ACMG guidelines14 (Table 
S1). A minimal set of genetic, clinical and laboratory features have already been published in Chen et 
al., supplementary table ST15.9 For this study, we expanded clinical and laboratory phenotype 
studies for the H181Y and R184P variants, because these GFI1B variants had similar functional effects 
in the MEG-01 cell models as the proven pathogenic GFI1B-Q287* variant. In addition, we performed 
clinical and laboratory phenotype studies for R190W variant carriers. 
 The variants G139S and G198S were classified as ‘Benign’ as they showed similar inhibition of 
MEG-01 expansion as wild type GFI1B, and have a relatively high minor allele frequency in gnomAD. 
Further, the thrombocytopenia in patient P9 with G198S was explained by a pathogenic ACTN1 
variant (p.R46Q)15. Variants R190W, C168F and Q89fs did not inhibit MEG-01 expansion to the same 
extent as wild type GFI1B (loss of function effect). R190W platelets were weakly CD34-positive, but 
R190W in patients P8.1 and P8.2 did not co-segregate with bleeding or result in abnormal α-granules 
(Table S1; Figures S3-5). Moreover, patient P7 with the same R190W variant was explained by a 
pathogenic variant in WAS (p.R364*), resulting in a ‘Benign’ classification for R190W. Patient P4 with 
a homozygous C168F variant suffered from clinical bleeding symptoms with thrombocytopenia and 
platelet aggregation dysfunction. Unlike P4, heterozygous C168F patients studied by Rabbolini and 
colleagues only displayed macrothrombocytopenia with platelet CD34 expression (partial effect on 
the phenotype).7 C168F is predicted to disrupt znf1 structure and thereby GFI1B function.9 This was 
confirmed in functional experiments performed here (Figure 1D) and by Rabbolini et al. showing that 
C168F disrupts the repressive function of GFI1B gene expression.7 C168F was classified as a ‘variant 
of unknown significance’ (VUS); further studies in the affected patient or of family members was not 
possible. A 90-year old woman (deceased) carrying the Q89fs variant and without affected siblings 
had mild thrombocytopenia with bleeding, platelet dysfunction and significantly reduced α-granule 
numbers; a phenotype very similar to previously described GFI1B pathogenic variants (Table S1; 
Figure S5).1, 2, 4 The Q89fs variant does not repress the Gfi1 promoter to the same degree as wild type 
GFI1B and the missense variants. However, it must be noted that we could only detect the truncated 
protein after proteasome inhibition, suggesting it is instable (Figure S6). If this is also the case in 
patient cells, the Q89fs variant would lead to haploinsufficiency. This variant was classified as VUS. 
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 The R184P and H181Y variants stimulated MEG-01 proliferation and failed to repress 
endogenous GFI1B expression in a similar way as the pathogenic Q287* variant. These missense 
variants were absent from the gnomAD database and co-segregation studies were performed (Figure 
3). Both the propositus (P6.1) and her father (P6.2), who are carriers of R184P, showed a small 
number of hypogranular platelets and platelet CD34 expression (Table S1; Figures S3-4). P6.1 had a 
normal platelet count whereas her father (P6.2) had mild thrombocytopenia. Importantly, neither 
parent had clinical bleeding symptoms or platelet dysfunction (Table S1; Figure 3A). Following ACMG 
criteria, the R184P variant was classified as VUS. For the propositus (P5.1) with the H181Y variant, 
three affected relatives (P5.2, P5.4-5) and one non-affected (P5.3) relative were screened and the 
variant co-segregated with clinical bleeding symptoms, platelet dysfunction and CD34-positive 
platelets (Table S1; Figure S3; Figure 3B). Affected individuals P5.1 and P5.2 had normal platelet 
counts with few large platelets and a significant reduction of α-granules (Table S1; Figures S4-5). The 
functional and segregation data suggest that the H181Y variant is causal of bleeding and platelet 
dysfunction but does not result in thrombocytopenia. Following ACMG guidelines, H181Y was 
classified as a VUS (Table S1).  
 We conclude Q89fs, C168F, H181Y, and R184P affect GFI1B function, but are not necessarily 
sufficient to cause bleedings on their own. Still, their identification and documentation, even when 
classified as VUS, will help to distinguish pathological from non-pathological GFI1B variants and 
increase our understanding of GFI1B functional domains. The identification of additional patients 
with similar variants will be essential to clarify their exact role for platelet phenotypes and bleeding. 
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Figure legends  
 
Figure 1. GFI1B variants have different effects on GFI1B function. Expansion competition cultures of 
MEG-01 cells transduced with flag-tagged GFI1B variants (A) G139S (B) G198S (C) R190W (D) C168F 
(E) Q89fs (F) H181Y (G) R184P. GFI1B-Q287*-flag, GFI1B-p37-flag wild type (WT), and empty vector 
(EV) were taken along as controls. Fold change of GFP% to GFP% at day 5 (first GFP measurement) is 
presented on the y-axis. Results show mean ± standard error of the mean, and two-tailed paired t-
tests were performed on day 26 to determine statistical significance *P<0.05, **P <0.01. Of note, all 
MEG-01 transduced cells showed increased GFI1B mRNA expression indicating expression of the 
retroviral vector (Figure S2).  
 
Figure 2. Functional effect of GFI1B variants H181Y and R184P. (A-B) Expansion competition cultures 
of MEG-01 cells transduced with flag-tagged GFI1B-H181Y+Q287* (A), or GFI1B-R184P-Q287* (B). 
Empty vector (EV) and GFI1B-Q287*-flag transduced cells taken along as reference. (C) Dual 
luciferase reporter assays in HEK293FT cells transfected with Renilla luciferase construct, Gfi1 
promoter Firefly luciferase construct, and empty vector (EV), wild type GFI1B-p37-flag (WT-p37), wild 
type GFI1B-p32-flag (WT-p32, lacking coding exon 4 and therefore amino acids 171-216 
corresponding to zinc finger 1 and 2), or GFI1B-flag variants. Firefly/Renilla luciferase ratios are 
normalized to EV transfected cells. Results show mean ± standard deviation, and two-tailed paired t-
tests were performed to determine statistical significance between WT-p37 and the other conditions. 
Corresponding Western blots showing expression of the flag-tagged GFI1B proteins and the GAPDH 
loading control are depicted below the graph. (D) 5’UTR GFI1B expression in GFP positive cells from 
MEG-01 expansion competition cultures, FACS-sorted 23 days after transduction. GFI1B expression is 
normalized to GAPDH expression. Results show mean ± standard deviation, and two-tailed paired t-
tests were performed to determine statistical significance. (E) Expansion competition cultures of 
MEG-01 cells transduced with flag-tagged GFI1B-H181Y+P2A, or GFI1B-R184P-P2A. EV transduced 
cells taken along as reference.  *P<0.05, **P <0.01, ***P <0.001 
 
Figure 3. Pedigrees for families harboring GFI1B variants H181Y (A) and R184P (B). The propositus 
(arrow) and the family members with signs of pathological bleeding are indicated with a black filled 
symbol. GFI1B variant status, patient identifier, platelet count (PLT), platelet CD34 expression, and 
the ISTH bleeding assesment tool (BAT) score are indicated for each patient. Normal range for the 
ISTH BAT score is <4 in adult males, <6 in adult females and <3 in children. P5.4 has less haemostatic 
challenges than the other siblings. Additional clinical and laboratory data obtained in patient samples 
can be found in Table S1. 
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